Morning Trend | PEIJIA-B experiences a decline on low volume, will sudden news amplify momentum?
Peijia Medical (9996.HK) maintained a low-volume downward trend throughout the day on October 30, with funds generally adopting a wait-and-see approach in the innovative drug and medical device segments. Mainstream incremental capital has not entered the market, and the stock price is operating at the lower end of the consolidation range, forming a downward momentum technically. The company has recently lacked positive disclosures regarding R&D or industrial implementation, and there has been no strong catalyst for the innovative drug market recently, with market evaluations remaining conservative. On the technical side, trading volume continues to be sluggish, and right-side incremental capital has yet to be activated. Some investors and analysts are focusing on foreign capital pharmaceutical ETFs and liquidity signals in Hong Kong's pharmaceutical sector, hoping to form a new trend guidance. Short-term strategies remain primarily defensive with low positions. If there are intraday capital fluctuations or key industry news resonances, it may become a turning point for a rebound. Before that, it is advisable to wait patiently and avoid blindly increasing positions at high prices. In the future, changes in policies or external news may suddenly amplify momentum, potentially bringing about short-term opportunities, but caution should be exercised against sudden negative news
Peijia Medical (9996.HK) maintained a low-volume downward trend throughout the day on October 30, with funds in the innovative drug and medical device segments generally adopting a wait-and-see approach. Mainstream incremental capital has not entered the market, and the stock price is operating at the lower end of the consolidation range, forming a downward momentum technically.
The company has recently lacked positive disclosures regarding R&D or industrial implementation, and there has been no strong catalyst for the innovative drug market recently, with market evaluations still leaning towards conservatism. On the technical side, trading volume continues to be sluggish, and right-side incremental capital has yet to be activated. Some investors and analysts are focusing on foreign capital pharmaceutical ETFs and liquidity signals in the Hong Kong pharmaceutical sector, hoping to form a new trend guidance.
Short-term strategies remain primarily defensive with low positions. If there are intraday capital fluctuations or resonance with key industry news, it may become a turning point for a rebound. Before that, it is advisable to wait patiently and avoid blindly increasing positions at high prices. In the future, changes in policies or external news may suddenly amplify momentum, potentially bringing about short-term opportunities, but caution should be exercised against sudden negative news
